Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292163 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2MAOBMAOANISCHHPGD | |
| SCHEMBL20525259 | 0.85 | MAOA (0.38) | SMN1; SMN2MAOBMAOANISCHHPGD | |
| SCHEMBL20525260 | 0.81 | HDAC3 (0.36) | SMN1; SMN2MAOBMAOANISCHHPGD | |
| SCHEMBL30474414 | 0.78 | MAOB (0.38) | MAOBADORA3CYP19A1 | |
| SCHEMBL26106057 | 0.78 | TDP1 (0.40) | SMN1; SMN2MAOBTSHRCYP19A1HTT | |
| SCHEMBL26107947 | 0.78 | MAOB (0.38) | SMN1; SMN2MAOBCYP19A1MAPT | |
| SCHEMBL9327125 | 0.77 | POLB (0.56) | SMN1; SMN2MAOBMAOANISCHHPGD | |
| SCHEMBL1783171 | 0.77 | MAOB (0.43) | SMN1; SMN2MAOBMAOANISCHHPGD | |
| Hydrochloric Acid SCHEMBL9751989 | 0.75 | POLB (0.55) | SMN1; SMN2MAOBMAOANISCHHPGD | |
| SCHEMBL26103189 | 0.74 | MAOB (0.51) | SMN1; SMN2MAOBMAOAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1035827-A | The 4-oxo of opticity-1-chromene-2-carboxylic acid derivative and intermediates preparation thereof | SANWA KAGAKU KENKYUSHO K K (JP) | 1989-09-27 | — | — | CN | claimed |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NONO INC. (CA) | 2024-09-12 | — | — | US | disclosed |
| US-20230285504-A1 | INHIBITION OF REPERFUSION INJURY WITH A PSD-95 INHIBITOR | NONO INC. (CA) | 2023-09-14 | — | — | US | disclosed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230055441-A1 | PLASMIN-RESISTANT PEPTIDES FOR TREATING STROKE AND RELATED CONDITIONS | NONO INC. (CA) | 2023-02-23 | — | — | US | disclosed |
| US-20190038760-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY | NONO INC (CA) | 2019-02-07 | — | — | US | disclosed |
| US-20170043030-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY | NONO INC (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9433685-B2 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory | NONO INC. (CA) | 2016-09-06 | — | — | US | disclosed |
| US-20150126460-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY | NONO INC. (CA) | 2015-05-07 | — | — | US | disclosed |
| US-8933013-B2 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory | NONO INC. (CA) | 2015-01-13 | — | — | US | disclosed |
| US-20120252731-A1 | Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory | NONO, INC. (CA) | 2012-10-04 | — | — | US | disclosed |
| WO-2007123941-A2 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-0163284-B1 | SUBSTITUTED CHROMANON-2-YL ALKANOLS AND DERIVATIVES THEREOF | G.D. Searle & Co. (US) | 1989-01-04 | — | — | EP | disclosed |
| EP-0163284-A2 | Substituted chromanon-2-yl alkanols and derivatives thereof | G.D. Searle & Co. (US) | 1985-12-04 | — | — | EP | disclosed |
| US-4546194-A | Substituted chromanon-2-yl alkanols and derivatives thereof | G. D. SEARLE & CO. (US) | 1985-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252731-A1 | Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory | CPA3, VIP, HAMP | SMN1; SMN2 4700/4885MAOB 2682/4885MAOA 3220/4885 |
| US-20150126460-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY | CPA3, VIP, HAMP | SMN1; SMN2 4700/4885MAOB 2682/4885MAOA 3220/4885 |
| US-20170043030-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY | CPA3, VIP, HAMP | SMN1; SMN2 4700/4885MAOB 2682/4885MAOA 3220/4885 |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | DAO, DNPEP, DDO | SMN1; SMN2 1603/4885MAOB 263/4885MAOA 365/4885 |
| US-20190038760-A1 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY | CPA3, VIP, HAMP | SMN1; SMN2 4700/4885MAOB 2682/4885MAOA 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.